Equities research analysts forecast that Protagonist Therapeutics Inc (NASDAQ:PTGX) will announce ($0.61) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Protagonist Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.56) and the lowest estimate coming in at ($0.70). Protagonist Therapeutics also posted earnings of ($0.61) per share in the same quarter last year. The firm is scheduled to issue its next earnings results on Wednesday, November 4th.
According to Zacks, analysts expect that Protagonist Therapeutics will report full-year earnings of ($2.55) per share for the current financial year, with EPS estimates ranging from ($2.70) to ($2.43). For the next year, analysts anticipate that the company will post earnings of ($2.16) per share, with EPS estimates ranging from ($2.96) to ($1.28). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Protagonist Therapeutics.
Several research firms recently issued reports on PTGX. BidaskClub upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 25th. Jefferies Financial Group began coverage on Protagonist Therapeutics in a report on Wednesday, July 15th. They issued a “buy” rating and a $27.00 price objective on the stock. SVB Leerink lifted their price objective on Protagonist Therapeutics from $17.00 to $30.00 and gave the stock an “outperform” rating in a report on Friday, May 22nd. Nomura lifted their price objective on Protagonist Therapeutics from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, Nomura Instinet lifted their price objective on Protagonist Therapeutics from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, May 11th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $26.58.
PTGX stock traded down $0.35 during trading on Tuesday, hitting $20.52. The stock had a trading volume of 206,595 shares, compared to its average volume of 354,098. The company has a debt-to-equity ratio of 0.03, a current ratio of 6.15 and a quick ratio of 6.15. Protagonist Therapeutics has a twelve month low of $4.47 and a twelve month high of $22.68. The stock has a market capitalization of $755.28 million, a P/E ratio of -8.05 and a beta of 1.49. The company’s 50-day moving average price is $18.01 and its two-hundred day moving average price is $13.04.
Several hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its position in shares of Protagonist Therapeutics by 30.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 57,072 shares of the company’s stock valued at $1,008,000 after buying an additional 13,168 shares during the period. Deerfield Management Company L.P. Series C purchased a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at approximately $17,898,000. RTW Investments LP raised its position in shares of Protagonist Therapeutics by 27.2% during the 2nd quarter. RTW Investments LP now owns 3,383,208 shares of the company’s stock valued at $59,747,000 after buying an additional 722,816 shares during the period. Artal Group S.A. purchased a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at approximately $2,472,000. Finally, BVF Inc. IL raised its position in shares of Protagonist Therapeutics by 241.9% during the 2nd quarter. BVF Inc. IL now owns 2,367,288 shares of the company’s stock valued at $41,806,000 after buying an additional 1,674,858 shares during the period. 93.09% of the stock is currently owned by hedge funds and other institutional investors.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.
Featured Article: Dividend Reinvestment Plan (DRIP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.